WARBURG PINCUS COMPLETES ACQUISITION OF BAUSCH & LOMB
`
`ROCHESTER, N.Y., October 26, 2007 — Bausch & Lomb (NYSE: BOL) and Warburg
`Pincus, the global private equity firm, announced today that affiliates of Warburg Pincus have
`completed the acquisition of Bausch & Lomb for a total purchase price of approximately $4.5
`billion, including approximately $830 million of debt.
`
`“With a strong and supportive partner in Warburg Pincus, we are well-positioned to create
`new opportunities for Bausch & Lomb and advance our leadership in the eye health industry,”
`said Ronald L. Zarrella, chairman and CEO of Bausch & Lomb. “Our customers will continue
`to receive high levels of service, product quality and innovation, and our commitment to
`serving their needs remains steadfast. On behalf of Bausch & Lomb’s management and Board
`of Directors, I want to thank our shareholders and hard-working employees for their support
`throughout this process.”
`
`Commenting on the transaction, Elizabeth H. Weatherman, a Warburg Pincus Managing
`Director, said, “We’re delighted to be partners with Bausch & Lomb, a global leader in vision
`care, ophthalmic devices and pharmaceuticals. We look forward to helping the company build
`upon its rich heritage and premier brand in ophthalmology.”
`
`Bausch & Lomb stock will cease to trade on the New York Stock Exchange at market close
`today and will be delisted.
`
`Under the terms of the agreement, Bausch & Lomb shareholders are entitled to receive $65.00
`in cash for each share of Bausch & Lomb common stock that they hold. Letters of transmittal
`allowing Bausch & Lomb shareholders of record to deliver their shares to the paying agent in
`exchange for payment of the merger consideration will be distributed shortly after the closing.
`Shareholders of record should be in receipt of the letter of transmittal before surrendering
`their shares. Shareholders who hold shares through a bank or broker will not have to take any
`action to have their shares converted into cash, as such conversions will be handled by the
`bank or broker.
`
`Morgan Stanley acted as financial advisor to the Special Committee of the Bausch & Lomb
`Board of Directors and delivered a fairness opinion to the Special Committee. Wachtell
`Lipton Rosen & Katz acted as legal counsel to the Special Committee in this transaction.
`Banc of America, Citi, Credit Suisse and JPMorgan served as financial advisors to Warburg
`Pincus and arranged the debt financing for the transaction, and Cleary Gottlieb Steen &
`Hamilton LLP acted as legal advisor to Warburg Pincus.
`
`# # #
`
`SENJU EXHIBIT 2212
`LUPIN v SENJU
`IPR2015-01105
`
`PAGE 1 OF 2
`
`

`
`About Bausch & Lomb
`
`Bausch & Lomb is the eye health company dedicated to perfecting vision and enhancing life
`for consumers around the world. Its core businesses include soft and rigid gas permeable
`contact lenses and lens care products, and ophthalmic surgical and pharmaceutical products.
`The Bausch & Lomb name is one of the best known and most respected healthcare brands in
`the world. Founded in 1853, Bausch & Lomb is headquartered in Rochester, N.Y., and
`employs approximately 13,000 people worldwide. Its products are available in more than 100
`countries. More information about Bausch & Lomb can be found at www.bausch.com.
`
`About Warburg Pincus
`
`Warburg Pincus has been a leading private equity investor since 1971. The firm currently has
`approximately $20 billion of assets under management investing from nine offices around the
`world. Since inception, Warburg Pincus has invested $26 billion in 570 companies in 30
`countries and across a range of sectors, including healthcare, consumer and retail, industrial,
`financial services, energy, real estate and technology, media and telecommunications. The
`firm has invested $4.8 billion in healthcare-related companies around the world, including
`approximately $1.5 billion in medical devices and $1.65 billion in life science and
`pharmaceutical companies. Notable medical device and pharmaceutical investments include:
`American Medical Systems (Nasdaq: AMMD), ev3 (Nasdaq: EVVV), Kyphon (Nasdaq:
`KYPH), Tornier, Wright Medical Group (Nasdaq: WMGI), The Medicines Company
`(Nasdaq: MDCO), Zentiva (LSE: ZEND, PSE: ZENTIVA) and Harbin Pharmaceutical.
`Warburg Pincus counts among its other signature investments: Knoll (NYSE: KNL), Neiman
`Marcus, NeuStar (NYSE: NSR), Bharti Tele-ventures (BSE: Bharti) and WNS Global
`Services (NYSE: WNS). For more information please visit www.warburgpincus.com.
`
`Forward Looking Statement
`
`This news release contains, among other things, certain statements of a forward-looking nature relating to future
`events or the future business performance of Bausch & Lomb. Such statements involve a number of risks and
`uncertainties including those concerning the ability of the Company and the parties with which it contracts to
`develop and introduce products successfully as well as the risk factors listed from time to time in the Company's
`filings with the Securities and Exchange Commission, including but not limited to, its reports on Forms 10-K,
`10-Q, 12b-25, 8-K and its definitive proxy statement. Many of the factors that will determine the outcome of the
`subject matter of this communication are beyond the Company's ability to control or predict. The Company
`undertakes no obligation to revise or update any forward-looking statements, or to make any other forward-
`looking statements, whether as a result of new information, future results or otherwise.
`
`PAGE 2 OF 2